Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks rise as Asia rallies; Biffa falls on delay

Mon, 27th Jun 2022 09:09

(Alliance News) - Stock prices in London opened higher on Monday amid hopes of less aggressive monetary policy tightening by central banks, while Biffa shares fell after a delay to the publication of its annual results.

Global stock markets are recovering ground, as investors believe central banks could decide to raise interest rates by less than previously expected.

The FTSE 100 index was up 49.93 points, or 0.7%, at 7,258.74. The mid-cap FTSE 250 index was up 141.41 points, or 0.7%, at 19,265.12. The AIM All-Share index was up 6.99 points, or 0.8%, at 903.26.

The Cboe UK 100 index was up 0.6% at 723.60. The Cboe 250 was up 0.8% at 16,894.33 and the Cboe Small Companies up 0.1% at 13,508.71.

Paris and Frankfurt also were making gains. The CAC 40 stock index was up 0.9%, while the DAX 40 was up 1.2%.

In the FTSE 100, oil majors Shell and BP were up 1.8% and 1.1% respectively, tracking spot oil prices higher.

Brent oil was trading at USD113.81 a barrel Monday morning, up from USD113.44 late Friday.

Conversely, AstraZeneca was down 0.2%, even after two key breast cancer treatments were recommended for European approval.

AstraZeneca said its Lynparza treatment has been recommended for approval in the European Union by the Committee for Medicinal Products for Human Use for early breast cancer treatment, after positive phase-three results. Lynparza also demonstrated a statistically significant and clinically meaningful improvement in overall survival, reducing the risk of death by 32% versus placebo, the drugmaker said.

Separately, Astra said its Enhertu drug also has been recommended for approval in the European Union for patients with breast cancer. The CHMP based its positive opinion on results from the Destiny-Breast03 phase three trial, which were published in The New England Journal of Medicine. The trial results showed that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

Lynparza was co-developed by Astra with Merck & Co, while Enhertu was jointly developed with Daiichi Sankyo.

In the FTSE 250, PZ Cussons was up 1.1% after the personal care products maker said trading for the fourth quarter to May 31 continued to be in line with expectations despite a challenging trading environment.

The Carex, St Tropez and Imperial Leather products maker expects revenue for the financial year of GBP590 million, with full-year like-for-like revenue growth of 3% and fourth-quarter LFL growth of 7%. PZ Cussons recorded revenue of GBP603.3 million in financial 2021.

PZ Cussons said growth continues to be driven primarily by improvements in price mix, with limited impact on volumes. Its expectations for annual adjusted pretax profit are unchanged.

At the other end of the midcaps, Biffa was down 1.4% at 401.40 pence.

The waste management company said the release of its financial 2022 results will be delayed, as it has requested additional time to complete the audit procedures related to its landfill tax enquiry.

Biffa said the results will be released as soon as auditor Deloitte has completed its work and expects adjusted results in line with earlier trading updates. Biffa's financial year ended in March.

Earlier this month, Biffa said it had received a series of "unsolicited and indicative" proposals from private equity firm Energy Capital Partners LLC, an investor in the fields of energy transition, renewables and infrastructure. It said it was "minded to recommend" a possible offer of 445p per share in cash, valuing Biffa around GBP1.36 billion.

Elsewhere, Wise was up 0.3%, even after the money transfers provider said the UK regulator is investigating its chief executive after a tax breach.

Wise said the UK Financial Conduct Authority has opened an investigation into Co-Founder & Chief Executive Officer Kristo Kaarmann.

Wise said that UK tax collector HM Revenue & Customs in September of last year updated its published list of individuals and businesses receiving penalties for a deliberate default regarding their tax affairs. Kaarmann was included on the list and will remain so for 12 months from its publication.

Following Kaarman's inclusion on the list, the board of Wise had conducted an investigation with the help of external legal counsel and shared the findings of this with the FCA.

Wise said Kaarmann intends to cooperate fully with the FCA in its investigation.

In Asia on Monday, the Japanese Nikkei 225 index closed up 1.4%. In China, the Shanghai Composite ended up 1.8%, while the Hang Seng index in Hong Kong was 2.4% higher. The S&P/ASX 200 in Sydney closed up 1.9%.

The pound was quoted at USD1.2328 early Monday, up from USD1.2282 at the London equities close Friday.

The euro was priced at USD1.0580, up from USD1.0549. Against the yen, the dollar was quoted at JPY135.04 in London, lower against JPY135.10.

Gold stood at USD1,837.66 an ounce, higher against USD1,830.41 late Friday.

Monday's economic calendar has US durable goods orders data at 1330 BST. The week picks up pace with a US consumer confidence reading on Wednesday, eurozone unemployment data on Thursday, before inflation readings from the bloc on Friday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.